Venn Life Sciences is a European CRO with over 24 years’ experience in the management & resourcing of clinical trials. We have worked acrosss all phases of clinical research, with extensive experience in multiple therapeutic and device areas.

We have worked with leading pharmaceutical, biotech and medical device companies seeking to navigate the often difficult European clinical trial landscape. We have senior management teams that have worked internationally on a range of different trial sizes, who are directly involved in the preparation, management and implemention of study activities.

Over the years our high rate of repeat business highlights our commitment to give our clients a service that is over and above what is expected of a CRO. We understand the importance of fair pricing, attention to detail and consistency in terms of project teams. These qualities are what make us a leading CRO in Europe and with just under 300 trials completed, we have the capabilities to place therapeutically aligned clinical staff on all our sponsor projects.



http://vennlifesciences.com/

InnoVenn expands products and first sales in US
RNS
RNS Number : 2395J
Venn Life Sciences Holdings PLC
02 April 2015





Venn Life Sciences Holdings Plc

("Venn" or the "Company")



InnoVenn expands its Labskin product line and confirms first sales to the US



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that InnoVenn, the skin science division of Venn, has extended its product line and seen first sales in the US.



InnoVenn have introduced a new 12 well-plates version of the research grade human skin equivalent, Labskin. Labskin has traditionally been produced in 6 well-plate assays with unique qualities such as its ability to support microflora, improved barrier function and longer test window, positioning it as a world leader in the area of skin science research. The 6 well-plate provides a large area of skin for those requiring easy manipulation, application and sampling. It is ideally suited to large scale samples, repeated sampling and application protocols. In contrast the new 12 well-plates provide the same quality product but in a smaller format for study designs requiring additional technical and biological replicates. It allows Labskin to target a bigger market.



Labskin has established its utility in the cosmetic and dermatological skin research industries with key opinion leaders championing it as a viable alternative to testing products on human or animal skin. The European Union implemented a complete ban on animal testing for cosmetics in March 2013. This ban has led to the market seeking out viable and reliable alternatives for a host of different cosmetic and pharmaceutical products.



InnoVenn has also recently launched its United States service, shipping to a leading cosmetics, personal care and chemical testing group in Michigan who are carrying out tests to measure skin metabolism in different environments.



Commenting on this development Venn CEO, Tony Richardson stated: "This expansion of InnoVenn's product line illustrates that this part of the business is growing independently of the CRO business, which is our strategic plan, allowing InnoVenn to be well positioned to deliver on the full potential of its technology portfolio. Labskin continues to break barriers in terms of its capacity to replicate human skin and colonise microflora and we look forward to bringing Labskin to a global audience."

EUR 2m contract with leading European biotech
RNS
RNS Number : 8174P
Venn Life Sciences Holdings PLC
10 June 2015

10 June 2015

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")



Venn Signs €2m Contract with Leading European Biotech



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology, academic and medical device clients, announces today the signing of a €2m contract with a leading European Biotechnology company.



The Phase III study, in the area of Rheumatology, will cover multiple European countries, commences immediately and will run over 4 years with a high concentration of activity in year one. Venn has extensive experience in the management of Phase III trials with an excellent track record of multi-site and multi-cultural clinical trials. The contract win comes on the back of Venn reporting a 140% revenue increase in 2014 and €4.1m of new contracts in March of this year with a US based Biotechnology company.



Speaking about the agreement, Venn CEO, Tony Richardson stated: "The signing of this contract reinforces the continued success of our clinical and business development teams to win projects with leading international organisations. Venn has been steadily and continuously delivering on its strategy to win larger multi country scale contracts and to increase its footprint across Europe."

proactiveinvestors ,venn-life-sciences-riding-the-biotech-wave

Trading update
RNS
RNS Number : 8992V
Venn Life Sciences Holdings PLC
13 August 2015



Venn Life Sciences Holdings Plc

("Venn" the "Company" or the "Group")



Trading update



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces a strong first half of 2015 with the Company billing in excess of €4m, up 170% against the same period in 2014 (H1: €1.5m).



The Company has demonstrated continued growth throughout 2015 driven by contract wins amounting to over €9m in the period to 30 June 2015.



Commenting on the figures, Venn CEO, Tony Richardson said: "Our fee income figures highlight the steady and consistent growth of the Company year on year with both repeat business and organic growth contributing to our excellent results and ability to win projects internationally. Our market continues to grow steadily and with a healthy pipeline of prospects we are well positioned to deliver further growth."



Venn will announce its interim results for the six months ended 30 June 2015 on the 22 September 2015.

10:25 02/11/2016
Director Deals - Venn Life Sciences Holdings PLC (VENN)
Allan Wood, Chairman, bought 230,000 shares in the company on the 31st October 2016 at a price of 21.67p. The Director now holds 230,000 shares. NOTE: Average price over 2 transactions. Story provided by StockMarketWire.com Director deals data provided by www.directorsholdings.com